journal article·2017-06-27

Household Fluorescent Lateral Flow Strip Platform for Sensitive and Quantitative Prognosis of Heart Failure Using Dual-Color Upconversion Nanoparticles

MinLi You, Min Lin, Yan Gong, Shurui Wang, Ang Li, Lingyu Ji, Haoxiang Zhao, Kai Ling, Ting Wen, Yuan Huang, Dengfeng Gao, Qiong Ma, Tingzhong Wang, Aiqun Ma, Xiaoling Li, Feng Xu

ACS Nano· Volume 11· Issue 6
Publisher page

Abstract

Heart failure (HF) is the end-stage of cardiovascular diseases, which is associated with a high mortality rate and high readmission rate. Household early diagnosis and real-time prognosis of HF at bedside are of significant importance. Here, we developed a highly sensitive and quantitative household prognosis platform (termed as UC-LFS platform), integrating a smartphone-based reader with multiplexed upconversion fluorescent lateral flow strip (LFS). Dual-color core-shell upconversion nanoparticles (UCNPs) were synthesized as probes for simultaneously quantifying two target antigens associated with HF, i.e., brain natriuretic peptide (BNP) and suppression of tumorigenicity 2 (ST2). With the fluorescent LFS, we achieved the specific detection of BNP and ST2 antigens in spiked samples with detection limits of 5 pg/mL and 1 ng/mL, respectively, both of which are of one order lower than their clinical cutoff. Subsequently, a smartphone-based portable reader and an analysis app were developed, which could rapidly quantify the result and share prognosis results with doctors. To confirm the usage of UC-LFS platform for clinical samples, we detected 38 clinical serum samples using the platform and successfully detected the minimal concentration of 29.92 ng/mL for ST2 and 17.46 pg/mL for BNP in these clinical samples. Comparing the detection results from FDA approved clinical methods, we obtained a good linear correlation, indicating the practical reliability and stability of our developed UC-LFS platform. Therefore, the developed UC-LFS platform is demonstrated to be highly sensitive and specific for sample-to-answer prognosis of HF, which holds great potential for risk assessment and health monitoring of post-treatment patients at home.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Luminescence Properties of Advanced Materials · Nanoplatforms for cancer theranostics · Biosensors and Analytical Detection

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Xi’an Diandi Biotech Company, Xi’an 710049, P. R. China

Department of Cardiology, Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710000, Shaanxi, China

Department of Cardiovascular Medicine, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, Shaanxi, China

Funding

Ministry of Education of the People's Republic of China · Ministry of Science and Technology of the People's Republic of China · National Natural Science Foundation of China · Key Laboratory of Space Nutrition and Food Engineering, China Astronaut Research and Training Center

References (42)

Show source-provided references
1. Chronic Heart Failure: National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care;Royal College of Physicians:London, 2010.
2. 10.1161/CIRCULATIONAHA.112.12543510.1161/CIRCULATIONAHA.112.125435 ↗
3. 10.1016/j.jchf.2016.05.00110.1016/j.jchf.2016.05.001 ↗
4. 10.1016/j.amjcard.2015.01.03710.1016/j.amjcard.2015.01.037 ↗
5. 10.1007/s00392-015-0811-x10.1007/s00392-015-0811-x ↗
6. 10.1016/j.bios.2013.10.07510.1016/j.bios.2013.10.075 ↗
7. 10.1016/j.bios.2015.06.06510.1016/j.bios.2015.06.065 ↗
8. 10.1007/s12274-015-0870-310.1007/s12274-015-0870-3 ↗
9. 10.1021/ac500540z10.1021/ac500540z ↗
10. 10.1016/j.bios.2011.04.03510.1016/j.bios.2011.04.035 ↗
11. 10.1016/j.bios.2015.12.00510.1016/j.bios.2015.12.005 ↗
12. 10.1016/j.bios.2014.09.02810.1016/j.bios.2014.09.028 ↗
13. 10.1016/j.talanta.2014.08.07610.1016/j.talanta.2014.08.076 ↗
14. 10.1021/nn300303q10.1021/nn300303q ↗
15. 10.1002/anie.20100515910.1002/anie.201005159 ↗
16. 10.1039/C4TC02034K10.1039/C4TC02034K ↗
17. 10.1021/ac501045810.1021/ac5010458 ↗
18. 10.1016/j.biotechadv.2012.04.00910.1016/j.biotechadv.2012.04.009 ↗
19. 10.1039/c3nr06549a10.1039/c3nr06549a ↗
20. 10.1371/journal.pntd.000294410.1371/journal.pntd.0002944 ↗
21. 10.1371/journal.pone.010530510.1371/journal.pone.0105305 ↗
22. 10.1002/adma.20040077210.1002/adma.200400772 ↗
23. 10.1002/adfm.20090023410.1002/adfm.200900234 ↗
24. 10.1038/srep0777910.1038/srep07779 ↗
25. 10.1039/C4TC00129J10.1039/C4TC00129J ↗
26. 10.1039/b809132n10.1039/b809132n ↗
27. 10.1039/b820254k10.1039/b820254k ↗
28. 10.1039/C5LC00055F10.1039/C5LC00055F ↗
29. 10.1016/j.biomaterials.2011.08.07610.1016/j.biomaterials.2011.08.076 ↗
30. 10.1039/C6LC00518G10.1039/C6LC00518G ↗
31. 10.1186/cc1144010.1186/cc11440 ↗
32. 10.4081/monaldi.2007.44810.4081/monaldi.2007.448 ↗
33. 10.1016/j.cca.2012.06.02110.1016/j.cca.2012.06.021 ↗
34. 10.1016/j.cca.2015.10.01510.1016/j.cca.2015.10.015 ↗
35. 10.1021/acs.analchem.6b0142710.1021/acs.analchem.6b01427 ↗
36. 10.1039/c3lc50672j10.1039/c3lc50672j ↗
37. 10.1002/adhm.20177000510.1002/adhm.201770005 ↗
38. 10.1039/C6NR01353H10.1039/C6NR01353H ↗
39. 10.1016/j.actbio.2016.07.03010.1016/j.actbio.2016.07.030 ↗
40. 10.1039/C4NR06944G10.1039/C4NR06944G ↗
41. 10.1039/C2BM00087C10.1039/C2BM00087C ↗
42. 10.1039/C5LC01388G10.1039/C5LC01388G ↗